Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)

Trial Profile

A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2018

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AIM-HN/SEQ-HN
  • Sponsors Kura Oncology
  • Most Recent Events

    • 05 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 05 Nov 2018 According to a Kura Oncology media release, additional data from this Phase 2 trial will be available in 2019.
    • 05 Nov 2018 According to a Kura Oncology media release, Kura Oncology Initiates Registration-Directed Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinomas.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top